Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of ...

Novo Nordisk, after mulling the implications of a phase 3 fail ... the only CKD program still listed in Novo’s pipeline is ...

Novo Nordisk, the maker of Ozempic ... It is marketed under brand names such as Ozempic, Wegovy, and Rybelsus, each approved ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Novo Nordisk’sNOVO.B-1.06%decrease ... according to a new trial. Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with diabetes. This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company ...

However, what sets Rybelsus apart from its sibling treatments is that it is an oral pill, whereas Ozempic and Wegovy are administered via injection. For much of 2024, Novo Nordisk has been ...